Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400320 | 0.89 | USP30 (0.47) | GPR119JAK2JAK1USP30GAA | |
| SCHEMBL2578274 | 0.83 | SMN1; SMN2 (0.46) | GPR119JAK2JAK1USP30GAA | |
| SCHEMBL16392288 | 0.83 | GPR119 (0.46) | GPR119JAK2JAK1USP30GAA | |
| SCHEMBL5089830 | 0.81 | GAA (0.45) | GPR119JAK2JAK1GAATHRB | |
| SCHEMBL2581606 | 0.81 | OPRD1 (0.41) | MEN1KMT2A | |
| SCHEMBL27879767 | 0.81 | OPRD1 (0.41) | MEN1KMT2A | |
| SCHEMBL5085617 | 0.80 | GAA (0.45) | GPR119JAK2JAK1GAATHRB | |
| SCHEMBL2958942 | 0.80 | GPR119 (0.46) | GPR119USP30GAATHRBSMN1; SMN2 | |
| SCHEMBL2581288 | 0.79 | FAAH (0.39) | FAAHMEN1KMT2A | |
| SCHEMBL15312890 | 0.79 | GPR119 (0.47) | GPR119THRBFAAHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586611-B2 | Fungicidal carboxamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-1948649-B1 | FUNGICIDAL CARBOXAMIDES | DU PONT (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20110269712-A1 | Fungicidal Carboxamides | BISAHA JOHN JOSEPH | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269712-A1 | Fungicidal Carboxamides | NAT1, PFAS, CHRM1 | GPR119 1256/4885JAK2 2023/4885JAK1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.